Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors

Hebin Che,Qi Xiong,Jinxia Ma,Shixue Chen,Huan Wu,Hongli Xu,Baicun Hou
DOI: https://doi.org/10.1186/s12885-022-10004-9
IF: 4.638
2022-08-19
BMC Cancer
Abstract:Accumulating evidence has revealed that the gut microbiota influences the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. As a part of the human microbiome, Helicobacter pylori (H. pylori) was reported to be associated with reduced effectiveness of anti-PD1 immunotherapy in patients with non-small-cell lung cancer (NSCLC). Gastric cancer is more closely related to H. pylori, so we conducted a retrospective analysis to verify whether the association of H. pylori and effectiveness is applicable to advanced gastric cancer (AGC) patients.
oncology
What problem does this paper attempt to address?